Expert advisers to the Centers for Disease Control and Prevention will meet on Thursday for discussion on what federal health officials see as a concerning increase in the rates of a rare but serious blood clotting disorder linked to Johnson & Johnson’s coronavirus vaccine.
The Advisory Committee on Immunization Practices will see new data at the meeting that shows elevated risks of the condition in men and women, according to one federal official, setting the stage for the experts to possibly recommend new restrictions on the use of the vaccine.
The F.D.A. on Tuesday said that although problems arose in men and women, the highest rate was in about 1 in 100,000 in women aged 30-49.
Among the women who were diagnosed with the syndrome, which can impair clotting and cause internal bleeding, about one in seven of them died, the F.D.A. said. The federal official who described the planning for Thursday’s meeting said that updated figures showed roughly nine deaths from the disorder.
The panel on Thursday may advise that the vaccine only be given to people who cannot access a different brand or who want it despite the risk, or restrict it to certain groups.
The Washington Post first reported the plans for Thursday’s meeting and the new federal data.
Jake Sargent, a spokesman for Johnson & Johnson, said the company shares with regulators reports of side…
